• Type:
  • Category:

Carl Zeiss Meditec AG Financial Results 9M 2021/22 | Performance & Future Growth with CEO and CFO

Share

Carl Zeiss Meditec AG 9M 2021/22: Key Takeaways

Company Performance Overview

In an update to investors, Carl Zeiss Meditec AG revealed its financial achievements and strategic advances for the first nine months of the fiscal year 2021/22. Under the leadership of CEO Dr Markus Weber and the CFO, the company showcased a notable revenue growth of 11.2% year-over-year, reaching €1,332.9 million, alongside a remarkable 36.0% surge in order intake. Despite the global supply chain challenges and the pandemic’s impact, particularly evident in the lockdowns in Shanghai, Carl Zeiss Meditec has not only navigated these hurdles with resilience but also capitalised on strategic opportunities across its Ophthalmic Devices and Microsurgery units, leading to disproportionate growth in orders compared to revenue.


Strategic Business Unit and Regional Performance

The company has demonstrated a diversified strength with contributions from all strategic business units and regions. In the Ophthalmic Devices sector, an 11.2% growth was recorded, significantly fueled by recurring revenue streams. Similarly, the Microsurgery segment witnessed an 11.2% increase in revenue. Geographically, the EMEA, Americas, and APAC regions all reported upward trends, with notable performances in core European markets, the United States, South America, China, and India.


Financial Highlights

Financially, the EBIT margin slightly declined to 20.7% due to planned high investments in Sales & Marketing and R&D, despite a close-to-previous-year operating result of €275.9 million. The detailed presentation underscored Carl Zeiss Meditec’s strategic focus on increasing recurring revenue streams and investing to ensure sustained growth above a 20% EBIT margin in the medium term.


Investor Outlook

As Carl Zeiss Meditec AG continues to navigate the complexities of the global market with a strong financial foundation and strategic foresight, investors are given a clear vision of the company’s robust health and ambitious growth trajectory for the remainder of the fiscal year and beyond.

Resources
Presentation
Carl Zeiss Meditec Video Hub
Podcast
Host
weber - Carl Zeiss Meditec AG Financial Results 9M 2021/22 | Performance & Future Growth with CEO and CFO -%sitename%

Dr. Markus Weber
CEO | Carl Zeiss Meditec AG

cfo - Carl Zeiss Meditec AG Financial Results 9M 2021/22 | Performance & Future Growth with CEO and CFO -%sitename%

Justus Felix Wehmer
CFO | Carl Zeiss Meditec AG

Linkedin
sebastian 1 - Carl Zeiss Meditec AG Financial Results 9M 2021/22 | Performance & Future Growth with CEO and CFO -%sitename%

Sebastian Frericks
Head IR | Carl Zeiss Meditec AG

Linkedin Envelope
Share
T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Discover Additional Elevator Pitches

Release Date

August 5, 2022

Duration

02:51

Director

Reviews for Carl Zeiss Meditec AG Financial Results 9M 2021/22 | Performance & Future Growth with CEO and CFO
There are currently no reviews for Carl Zeiss Meditec AG Financial Results 9M 2021/22 | Performance & Future Growth with CEO and CFO
COMPANIES:

Germany:

Austria:

Estonia:

Finland:

France:

Italy:

Poland:

Spain:

PRESENTATIONS:
INDUSTRIES:
Linkedin Twitter Instagram Podcast Envelope Whatsapp

(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

 

Scroll to top